Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study

BACKGROUND: This double-blind, parallel-group, multicenter, phase-3 study was designed to test the noninferiority of paliperidone palmitate 3-month formulation (PP3M) to the currently marketed 1-month formulation (PP1M) in patients (age 18–70 years) with schizophrenia, previously stabilized on PP1M....

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Int J Neuropsychopharmacol
Autori principali: Savitz, Adam J., Xu, Haiyan, Gopal, Srihari, Nuamah, Isaac, Ravenstijn, Paulien, Janik, Adam, Schotte, Alain, Hough, David, Fleischhacker, Wolfgang W.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2016
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4966278/
https://ncbi.nlm.nih.gov/pubmed/26902950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ijnp/pyw018
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi